Concurrent treatment of tuberculosis (TB) and HIV infection is challenging, given drug--drug interactions, overlapping toxicities, and worsening clinical symptoms due to immune reconstitution ...

New Data to be Presented at IDWeek 2024 Reinforce Merck’s Broad and Diverse Vaccines and Infectious Disease Pipeline and ...

On Wednesday, Gilead Sciences, a US-based pharmaceutical company, issued royalty-free licenses to 6 generic drug ... antiretroviral therapy due to issues like resistance, intolerance, or safety ...

Anemia prevalence was high in adult patients with HIV infection on HAART, with female sex, older age, and nonsuppressed viral load status identified as significant predictors.

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

See privacy policy. [LIMA, PERU] Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has proven highly effective in human trials, ...

Professor of medicine and deputy director of the Desmond Tutu HIV Centre at the Institute of Infectious Disease and Molecular Medicine, University of Cape Town A new drug to prevent HIV infection ...

Specific gene sequences are compared with that of a reference (wild-type) virus, and mutations associated with decreased susceptibility to specific antiretroviral drugs are identified. HIV ...

The antiretroviral drug has been hailed as a potential game-changer in the fight against HIV, with early trials finding the treatment 100 percent effective in preventing HIV infection. With ...

Hetero said Lenacapavir was a breakthrough HIV-1 capsid inhibitor that works with other antiretroviral drugs to treat multi-drug-resistant HIV-1 infections. “We will bring quick access to ...

Lenacapavir is a United States Food and Drug ... type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral ...

Lenacapavir is not approved for the prevention of HIV, but has regulatory nod in multiple countries, including U.S., for treatment of multi-drug-resistant HIV in combination with other ...